{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-124047","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2023-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.482089+00:00","generated_at":"2026-06-07T17:03:58.340299+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AbbVie to acquire Cerevel Therapeutics for $45/share (~$8.7B equity value)","bullets":["Transaction valued at $45.00 per Cerevel share, total equity ~$8.7B; approved by both boards.","Cerevel's late-stage asset emraclidine is a potential best-in-class antipsychotic for schizophrenia.","Deal expected to close mid-2024, subject to Cerevel shareholder vote, regulatory approvals, and customary conditions.","Acquisition adds multiple clinical assets: tavapadon (Parkinson's), CVL-354 (MDD), darigabat (epilepsy/panic).","AbbVie expects transaction to be accretive to adjusted diluted EPS beginning in 2030."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-124047","json":"https://secwatch.observer/filing/0001104659-23-124047.json","markdown":"https://secwatch.observer/filing/0001104659-23-124047.md","text":"https://secwatch.observer/filing/0001104659-23-124047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923124047/0001104659-23-124047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923124047/tm2332303d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T17:03:58.340299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}